HKMPY - Hikma Pharmaceuticals PLC

Other OTC - Other OTC Delayed Price. Currency in USD
47.70
0.00 (0.00%)
At close: 2:53PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close47.70
Open47.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range47.70 - 47.70
52 Week Range35.49 - 52.40
Volume100
Avg. Volume103
Market Cap5.337B
Beta (3Y Monthly)-0.34
PE Ratio (TTM)20.47
EPS (TTM)2.33
Earnings DateN/A
Forward Dividend & Yield1.04 (2.24%)
Ex-Dividend Date2019-04-04
1y Target EstN/A
  • Calculating The Fair Value Of Hikma Pharmaceuticals PLC (LON:HIK)
    Simply Wall St.17 days ago

    Calculating The Fair Value Of Hikma Pharmaceuticals PLC (LON:HIK)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Hikma Pharmaceuticals PLC (LON...

  • PR Newswire23 days ago

    Hikma Sponsors MIT Grand Hack to Support Global Healthcare Innovation

    The Grand Hack is MIT Hacking Medicine's annual flagship event dedicated to energise, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide.  More than 500 participants, mentors and sponsors from 25 US states and 29 countries are expected to gather on campus in the MIT Media Lab for this year's Grand Hack, the largest healthcare hackathon in the US. As a strategic sponsor, Hikma and its venture capital arm Hikma Ventures will support the Grand Hack's 'Personalised Medicine' theme, which focuses on solving challenges in improving preventative medicine, treatment affordability and personalised medicine dosages.  Hikma will also have representatives on-site to speak with those attendees interested in exploring opportunities to join Hikma in its mission of putting better health within reach of millions of people through its high-quality medicines and healthcare solutions.

  • PR Newswire24 days ago

    Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP

    "Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio," said Dan Motto, Executive Vice President, Commercial and Development, Injectables.

  • Hikma Pharmaceuticals PLC (LON:HIK): What’s The Analyst Consensus Outlook?
    Simply Wall St.2 months ago

    Hikma Pharmaceuticals PLC (LON:HIK): What’s The Analyst Consensus Outlook?

    In December 2018, Hikma Pharmaceuticals PLC (LON:HIK) announced its latest earnings update, which showed that the company turned profitable again after experiencing negative earnings in the previous financial year. Below,Read More...

  • ACCESSWIRE2 months ago

    Hikma Pharmaceuticals Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Hikma Pharmaceuticals Plc (OTC PINK: HKMPY ) will be discussing their earnings results in their 2018 Second Half Earnings to be held on March 12, 2019, 2018 ...

  • Reuters2 months ago

    Hikma guides for injectables growth after profit surge

    (Reuters) - Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent ...

  • What Investors Should Know About Hikma Pharmaceuticals PLC’s (LON:HIK) Financial Strength
    Simply Wall St.3 months ago

    What Investors Should Know About Hikma Pharmaceuticals PLC’s (LON:HIK) Financial Strength

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small and large cap stocks are widelyRead More...

  • Simply Wall St.5 months ago

    Read This Before Buying Hikma Pharmaceuticals PLC (LON:HIK) Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Business Wire6 months ago

    Hikma Demonstrates Support for US Pharmacists and Patient Safety

    Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices

  • U.K. Economy Grows at Fastest Pace in Nearly a Year: 5 Picks
    Zacks8 months ago

    U.K. Economy Grows at Fastest Pace in Nearly a Year: 5 Picks

    The football World Cup and unexpectedly warm weather led to a pickup in consumer spending.

  • Reuters9 months ago

    Hikma sees higher full-year revenue, shares climb

    The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain steady.

  • Should You Be Concerned About Hikma Pharmaceuticals PLC’s (LON:HIK) Investors?
    Simply Wall St.9 months ago

    Should You Be Concerned About Hikma Pharmaceuticals PLC’s (LON:HIK) Investors?

    I am going to take a deep dive into Hikma Pharmaceuticals PLC’s (LON:HIK) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...